Company intelligence / Profile preview
Nektar Therapeutics
San Francisco, California, United States of Americanektar.com ↗
- Ownership
- Public · NKTR
- Employees
- ~61
- Development stage
- Phase 2
01
Overview
Nektar has a history of developing novel immunomodulatory therapies using proprietary polymer chemistry. Recent clinical results include topline data from a Phase 2 study of rezpegaldesleukin in systemic lupus erythematosus. The company has reprioritized its pipeline following setbacks in late-stage trials and continues to focus on autoimmune and oncology indications with selective immune modulators
- Therapeutic areas
- OncologyImmunology
- Modalities
- Peptidesproteinsantibodiessmall moleculespolymer conjugates
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
Request access →03
Partnerships
Cellular Biomedicine Group (collaboration on NKTR‑255 for solid tumors)Multiple historical partnerships with major pharmaceutical companies for commercialization and co-development efforts
04
Financials
- Market cap
- $2.1B
- Total revenue
- $10.1M
- Enterprise value
- $1.6B
Beyond the preview
Go deeper on Nektar Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nektar Therapeutics.